Press Release
We are pleased to announce the publication of a research paper titled "Two independent modes of kidney stone suppression achieved by AIM/CD5L and KIM-1" in the scientific journal "Communications Biology." This paper explores the preventive and therapeutic effects of AIM on kidney stones.
Press Release Summary
Discovery of Preventive and Therapeutic Effects of AIM and KIM-1 on Kidney Stones
Authors
Toru Miyazaki (Director and President of the Institute for AIM Medicine)
Satoko Arai (Associate Professor, Graduate School of Medicine, The University of Tokyo / the Institute for AIM Medicine)
Natsumi Maehara (Senior Research Fellow, the Institute for AIM Medicine)
Kyohei Matsuura (Graduate School of Medicine, The University of Tokyo / Beyond Next Ventures Inc.)
Overview of the Presentation
Kidney stones, one of the most prevalent diseases, have been on the rise due to modernized lifestyles and dietary habits. While surgical removal is a common treatment, there is a lack of effective internal treatments or medications for preventing their occurrence and recurrence.
In this study, researchers from the Institute for AIM Medicine (IAM), led by Toru Miyazaki, have made significant findings regarding the prevention and treatment of kidney stones. Through experiments involving the growth of calcium oxalate crystals and studies using mice with induced kidney stones, the researchers have revealed several key points:
- AIM binds to calcium oxalate crystals, inhibiting their growth.
- Administering AIM intravenously once a day significantly suppresses kidney stone formation.
- The suppression of kidney stone growth can also be achieved by administering a specific peptide of AIM.
- AIM administration reduces inflammation by removing damage-associated molecular patterns (DAMPs), improving overall health.
- The kidney injury molecule -1 (KIM-1) molecule expressed in proximal tubule epithelial cells induces phagocytosis of existing kidney stones, reducing their presence.
These findings open doors for AIM and KIM-1 to become novel preventive and therapeutic drivers for kidney stones, addressing the lack of effective internal treatments and medications. Moreover, AIM holds potential as a preventative measure against kidney stone recurrence. These discoveries also offer insights into potential applications for genetic diseases involving oxalate crystals, i.e., primary hyperoxaluria type I.
The development of internal treatments involving AIM and KIM-1 could alleviate the financial burden associated with surgical treatments for kidney stones, benefiting a significant number of patients.
This study was conducted under the support of the Japanese government-funded program “Leading Advanced Projects for medical innovation (LEAP),” sponsored by Japan Agency for Medical Research and Development (AMED). The research results will be published online in Communications Biology on August 3, 2022 (Eastern Standard Time).
Publication Information
Journal: Communications Biology (Online Edition)
Title: Two independent modes of kidney stone suppression achieved by AIM/CD5L and KIM-1
DOI: 10.1038/s42003-022-03750-w
Authors: Kyohei Matsuura1, Natsumi Maehara1, 2, Ayaka Eguchi1, Aika Hirota1, 2, Keisuke Yasuda1, 2, Kaori Taniguchi1, Akemi Nishijima1,2, Nobuyuki Matsuhashi3, Yoshiyuki Shiga3, Yasuhiro Iguchi4, Kazunari Tanabe5, Satoko Arai1, 2 & Toru Miyazaki2
Affiliations: 1 University of Tokyo, 2 The Institute for AIM Medicine, 3 NTT Medical Center Tokyo, 4 Medical corporation JISEIKAI, 5 Tokyo Women's Medical University
Contact Information
Toru Miyazaki, Director and President, The Institute for AIM Medicine
Phone:
Fax:
Email:
Note This translation provides a comprehensive overview of the press release, summarizing the key points and findings of the research paper related to the preventive and therapeutic effects of AIM and KIM-1 on kidney stones. If you need further details or assistance with specific sections, feel free to ask.
